The University of Tennessee Health Science Center

11/05/2025 | News release | Distributed by Public on 11/05/2025 10:15

UTHSC News: Liza Makowski, PhD, Helps Lead Global Conversation on GLP-1 Drugs and Cancer Risk

Blockbuster drugs like Ozempic, Wegovy, and Zepbound have transformed obesity care for millions of Americans, making them some of the most talked-about medical breakthroughs of the decade. Yet several questions remain, including their long-term effects on cancer risk.

A new commentary co-authored by Professor Liza Makowski, PhD, associate director for Education and Development in the Center for Cancer Research at the University of Tennessee Health Science Center, examines the potential cancer-related consequences of glucagon-like peptide-1 (GLP-1) drugs.

Read more on the UT Health Science Center News website.

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

Related

The University of Tennessee Health Science Center published this content on November 05, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 05, 2025 at 16:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]